HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Iterum Therapeutics (NASDAQ: ITRM) and maintained a $6 price target.
May 31, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Iterum Therapeutics and maintained a $6 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $6 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100